We have examined the function of the epidermal growth factor (EGF) receptor, c-Src and focal adhesion kinase (FAK) in the progression of colon cancer using an in vitro progression model. A non-tumorigenic cell line was derived from a premalignant colonic adenoma (PC/AA) from which a clonogenic variant was established (AA/ C1). Following sequential treatment with sodium butyrate and the carcinogen N-methyl-N'-nitro-N-nitrosoguanidine an anchorage-independent line was isolated which, with time in culture, became tumorigenic when injected into athymic nude mice (AA/C1/SB10). We have shown that both EGF receptor and FAK protein levels were elevated in the carcinoma cells as compared to the adenoma cells, while the expression and activity of c-Src were unaltered during the adenoma to carcinoma transition. EGF induced the movement of the carcinoma cells into a reconstituted basement membrane which was not seen with the premalignant adenoma cells. This increased motility was accompanied by an EGF-induced increase in c-Src kinase activity, relocalisation of c-Src to the cell periphery and phosphorylation of FAK in the carcinoma cells but not in the adenoma cells. This suggests that c-Src plays a role in the biological behaviour of colonic carcinoma cells induced by migratory factors such as EGF, perhaps acting in conjunction with FAK to regulate focal adhesion turnover and tumour cell motility. Furthermore, although cSrc has been implicated in colonic tumour progression, we demonstrate here that in the adenoma to carcinoma in vitro model c-Src is not the driving force for this progression but co-operates with other molecules in carcinoma development.
Introduction
During the development of colon cancer a number of genetic events occur in the progression of a nonmalignant polyp to a malignant carcinoma (Fearon and Vogelstein, 1990) . However, the biological pathways reponsible for this conversion to a malignant phenotype are less well understood. In this study we have used a well characterised in vitro model of colon cancer progression (Williams et al., 1990) which provides an ideal system in which to study the role of three possible participants on human colonic epithelial tumour progression; epidermal growth factor (EGF) receptor, c-Src and focal adhesion kinase (FAK) .
Activation of the non-receptor tyrosine kinase c-Src occurs with high frequency during colon tumour development. An increase in speci®c kinase activity over that found in adjacent normal mucosa has been demonstrated (Bolen et al., 1987; Cartwright et al., 1989) with activation in colonic adenomas correlating with malignant potential (Cartwright et al., 1990) . More recently, premalignant ulcerative colitis epithelial which is at greatest risk from developing cancer has been shown to have elevated c-Src activity (Cartwright et al., 1994) . Further increases in c-Src activity are seen in metastatic tissues relative to the corresponding primary tumours Termuhlen et al., 1993) suggesting a possible link between elevation of c-Src activity and the metastatic process. Thus, there is a wide body of evidence implicating cSrc in colonic tumour progression but little detail exists on its biological role during this process.
The EGF receptor is a transmembrane receptor with intrinsic tyrosine kinase activity and there have been numerous reports on the expression of the receptor and its ligands, EGF and transforming growth factor a (TGFa) in colon tumours. In an immunocytochemical study synchronous expression of EGF and EGF receptors in highly invasive colon carcinomas suggested that an EGF autocrine loop may play a role in the regulation of these tumours (Karameris et al., 1993) . Such autocrine loops have been demonstrated in several colon carcinoma cell lines where cell growth was inhibited by using antisense TGFa and blocking antibodies to the EGF receptor (Karnes et al., 1992; Sizeland and Burgess, 1992; Watkins and Levine, 1991) . Antisense EGF receptor RNA and antisense TGFa inhibit both the growth and transformation of colon carcinoma cells Ciardiello et al., 1993; Rajagopal et al., 1995) and a recent report has demonstrated that expression of the EGF receptor in colon carcinoma cells directly correlates with their metastatic potential (Radinsky et al., 1995) . EGF promotes the migration and invasion of a number of cell types which has been linked to alterations in cell-extracellular matrix interactions (Chen et al., 1993; Fujii et al., 1995; Lund-Johansen et al., 1990; Sundareshan et al., 1991) . In ®broblasts c-Src synergistically increases the oncogenic activity of the EGF receptor suggesting that these two kinases may co-operate in the progression to a malignant phenotype (Maa et al., 1995) . c-Src activity has also been shown to be required for both the mitogenic eect of EGF in ®broblasts (Luttrell et al., 1988; Roche et al., 1995) , the migratory eects of EGF in epithelial cells (Rodier et al., 1995) and also the migration of endothelial cells (Bell et al., 1992) .
FAK was ®rst identi®ed as a tyrosine phosphorylated protein in v-src transformed ®broblasts which localized to focal adhesions (Schaller et al., 1992) . These are discrete cellular regions where integrins interact with extracellular matrix proteins. Tyrosine phosphorylation of FAK is also regulated by cell adhesion to extracellular matrix proteins, clustering of integrins, growth factors and neuropeptides (reviewed in . In ®broblasts FAK is involved in cell motility with FAK de®cient ®broblasts being impaired in their motility (Ilic et al., 1995) , while studies with epithelial cells have shown that FAK phosphorylation and expression correlates with increased motility (Akasaka et al., 1995; Matsumoto et al., 1994) . Furthermore increased expression of FAK is associated with invasive tumours of the colon and breast (Owens et al., 1995) . Activated c-Src is complexed with FAK through binding of its SH2 domain to Tyr 397, the FAK autophosphorylation site (Cobb et al., 1994; suggesting that the regulation of these two kinases may be linked.
We have examined the function of the EGF receptor, c-Src and FAK in the progression of colon cancer using an in vitro model of colon cancer progression in which a cell line was derived from a large colonic tubular adenoma with mild dysplasia (PC/AA). A clonogenic variant was established (AA/C1) and following sequential treatment with sodium butyrate and the carcinogen N-methyl-N'-nitro-N-nitrosoguanidine an anchorageindependent line was isolated which, with time in culture became tumorigenic when injected into nude mice (AA/C1/SB10) (Williams et al., 1990) . Both cellular and molecular changes seen in the progression of the PC/ AA cell line are similar to those observed in in vivo studies of colon cancer progression (Manning et al., 1991; Williams et al., 1993) indicating that this cell model represents a relevant in vitro system for further studies on the progression of the disease. Both the EGF receptor and FAK were elevated in the carcinoma cells as compared to the adenoma cells from which they were derived, while c-Src expression and activity was unaltered during the adenoma to carcinoma progression. It may be that c-Src was elevated during initiation or development of the adenoma as has been previously suggested (Cartwright et al., 1990) . EGF induced the movement of the carcinoma cells but not the premalignant adenoma cells into a reconstituted basement membrane. This was accompanied by an EGF-induced increase in c-Src kinase activity, relocalisation of c-Src to focal adhesions and phosphorylation of FAK in the carcinoma cells but not in the adenoma cells. This suggests a co-operation between the EGF receptor, c-Src and possibly FAK to induce properties in the carcinoma cells indicative of a more motile invasive phenotype.
Results

EGF receptor and c-Src expression
EGF receptor expression was threefold higher in the AA/C1 clonogenic adenoma cell line as compared to the parental PC/AA cell line with a further substantial increase in the AA/C1/SB10 carcinoma cell line as determined by immunoblotting and densitometry ( Figure 1a ). Scatchard analysis was carried out to determine the number of EGF receptors in the AA/C1 and AA/C1/SB10 cells (Table 1) . Both cell lines demonstrated a biphasic Scatchard plot (results not shown), indicating the presence of two types of binding sites with dierent anities for EGF consistent with reports in other colon cancer cell lines (Radinsky et al., 1995) . The majority of binding sites were of low anity, with K d values of 7.69 and 6.58 nM for AA/C1 and AA/C1/SB10 cells respectively. There was a 4.1-fold increase in total EGF receptor number per cell in the carcinoma cells as compared to the adenoma cells. The levels of c-Src protein were unaltered between the cell lines in the PC/AA adenoma progression sequence with the anchorage-independent, tumorigenic AA/C1/ SB10 cell line having equivalent protein levels to thosë P]ATP using enolase as a substrate found in the anchorage-dependent, non-clonogenic parental adenoma PC/AA cells (Figure 1b) . Furthermore, there was no dierence in c-Src kinase activity measured by immune complex kinase assays using enolase as a substrate, during the adenoma to carcinoma progression ( Figure 1c ). The PC/AA cell line was derived from a relatively large (3 ± 4 cm in diameter) tubular adenoma which would be judged to have a relatively high risk of developing into a malignant tumour. Previous work has shown that c-Src kinase activity was elevated in colonic polyps as compared to adjacent normal mucosa, with the highest activity seen in malignant polyps and benign polyps at greatest risk of developing cancer as judged by size, histology and degree of dysplasia (Cartwright et al., 1990) . It is likely that the c-Src activity in the parental PC/AA cell line is already increased above that found in the adjacent normal colonic epithelial cells from which the polyp was taken. Thus although there is a wide body of evidence implicating c-Src in colon tumour progression our data suggests that c-Src does not drive the progression of the adenoma line to a malignant phenotype but may cooperate with other proteins such as the EGF receptor which are upregulated during the progression.
Eect of EGF on cell growth and migration
In order to determine the biological contribution of the elevated EGF receptor levels to the carcinoma phenotype, we assessed the eect of EGF on cell growth and migration into reconstituted extracellular matrix components.
(a) Eect of EGF on cell growth As a number of studies have shown that EGF and TGFa act as autocrine growth factors for colon tumour cell lines we asked whether EGF could act as a mitogen for the cells which may lead to a growth advantage in the carcinoma cells where the EGF receptor levels are elevated ( Figure 1c ). Both the adenoma (AA/C1) and the carcinoma cells (AA/C1/SB10) were allowed to establish for 48 h in normal growth medium (CM) and were then grown in reduced serum conditions (CSS) in the presence of EGF over a 5 day period. Cell growth was determined using a tetrazolium dye reduction assay ( Figure 2 ). Very little growth of the AA/C1 adenoma cells was observed in the reduced serum conditions (CSS) and treatment with EGF did not alter their growth rate signi®cantly. In the AA/C1/SB10 carcinoma cells there was only a small growth advantage in the presence of 50 ng/ml EGF. This represents a 1.3-fold increase in cell growth in the EGF-treated cultures as compared to growth in reduced serum conditions, whereas the growth rate in normal growth medium was 3.7-fold greater than in the reduced serum conditions over the 5 day period.
Higher concentrations of EGF were growth inhibitory (results not shown). The small increase in the growth of the carcinoma cells in the presence of EGF could be inhibited by simultaneous addition of the EGF receptor tyrosine kinase inhibitor CGP52411. CGP52411 inhibits EGF receptor autophosphorylation in intact cells with an estimated IC 50 value of 1 ± 10 mM and in vitro the IC 50 for inhibition of c-Src was around 50 times higher than for the EGF receptor (Buchdunger et al., 1994) . In both cell lines growth in reduced serum conditions and in normal growth medium was not inhibited by CGP52411 suggesting that EGF or TGFa are not autocrine growth factors or major mitogens in the serum or conditioned medium for these cells. Short term mitogenesis experiments (24 h) using incorporation of [ 3 H]thymidine as an endpoint also failed to show a signi®cant increase in DNA synthesis in the presence of EGF in both cell lines (results not shown). Thus we conclude that EGF does not act as a strong mitogen in these colonic cell lines.
Figure 2 EGF-induced cell proliferation and inhibition by CGP52411. Cells were grown in medium supplemented with 1% charcoal-stripped serums (CSS) in the absence or presence of EGF (50 ng/ml) added daily for 5 days or in normal growth medium (CM). CGP52411 (5 mM) was added daily to cells where indicated. Cell number was determined after 5 days using a tetrazolium dye reduction assay. Each value is the mean+s.d. of four replicate wells taken from a representative experiment in a series of three Figure 3 Migration across collagen coated ®lters. AA/C1 adenoma and AA/C1/SB10 carcinoma cells were plated onto the top of collagen coated ®lters and allowed to adhere for 2 h after which migration of cells to the bottom of the ®lter was determined in the absence or presence of EGF. Results are expressed as the number of cells on the bottom of the ®lter as a percentage of the total number of cells in the assay. Each value is the mean of two ®lters taken from a representative experiment (b) Eect of EGF on cell migration and invasion As EGF does not provide a major growth stimulus for the cells we then asked whether EGF could induce movement of the cells into extracellular matrix components using an in vitro invasion assay (Hennigan et al., 1994) . This utilises the reconstituted basement membrane Matrigel which is layered over a porous membrane on which the cells are grown. Movement of cells from the ®lter into the Matrigel in response to growth factors such as EGF can then be monitored and quantitated using confocal microscopy. The above assay is dependent on two separate processes, migration across the ®lter and subsequent movement or invasion into the Matrigel. Type IV collagen is one of the main components of Matrigel. The migration of both cell lines across a type IV collagen coated ®lter over a 18 h period demonstrated that EGF did not eect the migration of either cell line across the ®lter and that both the adenoma and carcinoma cells were equally ecient at moving across the ®lter (Figure 3) .
The adenoma AA/C1 cells did not move signi®cantly into the Matrigel either in the absence or presence of EGF as determined by the absence of positive pixels within the Matrigel following propidium iodide staining (Figure 4a ). The carcinoma cell line (AA/C1/ SB10) had a low basal rate of invasion (4.5%) which was increased over a 5 day period to 13.4% in the presence of EGF (100 ng/ml) (Figure 4b) . Addition of the EGF receptor tyrosine kinase inhibitor CGP52411 inhibited the movement of the AA/C1/SB10 cells in response to EGF. Further analysis of the EGFdependent movement of the AA/C1/SB10 cell line demonstrated that it was dependent on both EGF concentration and time. Movement into the Matrigel was seen when the concentration of EGF reached 75 ng/ml, with a small further increase at 100 ng/ml (Figure 5b ). Increasing the EGF concentration further (200 ng/ml) had no further eect on the movement of the AA/C1/SB10 cells into the Matrigel and did not result in the movement of the AA/C1 adenoma cells (results not shown). After 3 days the cells had migrated across the ®lter but no signi®cant movement of cells into the Matrigel was observed until day 5. Extending the assay to 7 days gave only a small increase in the number of cells present in the Matrigel (Figure 5a ). Therefore we concluded that the dierence between the cell lines is an inability of the adenoma cells to move into the Matrigel in response to EGF and not an inability to migrate across the ®lter.
Changes in c-Src localisation and activity in response to EGF Having established that EGF was able to induce the movement of the carcinoma cell line (AA/C1/SB10) into Matrigel, we then asked whether c-Src was aected by this process. In untreated cells c-Src was found mainly within the cytoplasm, seen as diuse staining with some concentrated at cell-cell boundaries (Figure 6a and b) . Following EGF treatment of the adenoma cells there was no change in c-Src localisation, with the c-Src staining remaining diuse throughout the cytoplasm (Figure 6c ). In contrast, in the carcinoma cells (AA/C1/SB10) there was a redistribution of c-Src to discrete regions on the cell periphery 1 h after addition of EGF (Figure 6d and e) . Treatment of cells with CPG52411 prevented the relocalisation of c-Src in the AA/C1/SB10 cell (results not shown). This relocalisation of c-Src in the AA/C1/ SB10 cells was accompanied by a small but reproducible increase in c-Src kinase activity which was consistently seen in a number of independent experiments. This increase in activity was seen 10 min after addition of EGF and remained elevated for up to 4 h (Figure 7a ). This represented a 1.7-fold increase in c-Src kinase activity as determined by scanning densitometry (Figure 7b) . No increase in c-Src kinase activity was seen following EGF treatment of the adenoma AA/C1 cells (Figure 7a and b) .
Association of focal adhesion kinase (FAK) with the adenoma ± carcinoma progression As FAK has been implicated in epithelial cell motility and invasion and is a known eector of Src family kinases we investigated whether FAK might be involved in the movement of the colon epithelial cells into the reconstituted basement membrane Matrigel in response to EGF. An increase in FAK protein levels in the carcinoma cells (AA/C1/SB10) as compared to the late adenoma cells (AA/C1) was observed while there was no dierence in FAK protein levels between the parental (PC/AA) and clonogenic (AA/C1) adenoma cells (Figure 8a) . We showed by immuno¯uorescence that FAK was present at the leading edges of AA/C1/ SB10 carcinoma cells in the focal adhesions ( Figure   Figure 5 Quantitation of EGF-induced invasion into Matrigel. (a) Time dependence. The ability of AA/C1/SB10 cells to invade into Matrigel in the presence of 100 ng/ml EGF over a 7 day period was determined. (b) Dose-dependence. The ability of AA/ C1/SB10 cells to invade into Matrigel in response to a range of EGF concentrations over a 5 day period was determined. In both cases the % of cells invading 20 m or more into the Matrigel was calculated as described for Figure 4 8b). FAK staining in the adenoma cells was below the limit of detection, with the focal adhesions also being less abundant in the adenoma cells as compared to the carcinoma cells as determined using an antibody against vinculin (Figure 8c and d) . Both vinculin and FAK staining were unaltered in EGF treated cells (results not shown) demonstrating that targeting of these proteins to the focal adhesions was not dependent on EGF. However, the phosphorylation of FAK was increased following treatment of the carcinoma cells (AA/C1/SB10) with EGF ( Figure 8e) . FAK was phosphorylated 10 min after addition of EGF and remained phosphorylated for up to 1 h, being maximal (15-fold over untreated) after 30 min.
Discussion
The acquisition of an invasive phenotype is one of the de®ning features of malignancy. Here, we have identi®ed the EGF receptor, c-Src and FAK as components of a putative signalling pathway which is associated with induction of a more motile and invasive phenotype in colonic tumour cells in vitro. In a b
c d e Figure 6 Relocalisation of c-Src in response to EGF. AA/C1 (a, c) and AA/C1/SB10 cells (b, d, e) were ®xed and stained with an antibody to c-Src. All cultures were serum-starved for 16 h prior to ®xation. Cells in (c, d, e) were treated with EGF (100 ng/ml) for 1 h prior to ®xation particular we have examined the window of tumour development represented by the in vitro colonic adenoma to carcinoma progression of a cell line derived from a non-malignant adenoma (Williams et al., 1990) . Although some of the genetic changes which occur during progression in the in vitro model have been characterised and found to be similar to those that occur during the adenoma to carcinoma progression in vivo (Williams et al., 1993) , there is little information on the biochemical mediators of the behavioral transition which the cells undergo. Thus we examined the levels of the EGF receptor, c-Src and FAK, which have all been previously implicated in epithelial cell tumour progression. In particular there is a wide body of evidence that elevated levels of c-Src kinase activity is associated with colonic tumour progression (see Introduction). However, our data indicate that the level of c-Src protein and activity is unaltered as the parental adenoma cell line (PC/AA) progresses to the carcinoma cell line (AA/C1/SB10). Thus, c-Src is unlikely to be the driving force for this stage of colon carcinoma development, although the readily detectable endogenous activity implies that cSrc exists in these cells in an already active form and may be important in co-operating with other signalling molecules which are deregulated during progression, such as the EGF receptor and/or FAK.
Involvement of EGF receptor
The EGF receptor has also been implicated in colon tumour growth and requires c-Src for its mitogenic activity in ®broblasts (Luttrell et al., 1988; Roche et al., 1995) and migration in epithelial cells (Rodier et al., 1995) . We found that EGF receptor levels, as determined by both Scatchard anlaysis and protein expression, were increased during the progression of the parental adenoma line (PC/AA) to the clonogenic adenoma variant (AA/C1), with a further substantial elevation in the progression of the AA/C1 adenoma line to the carcinoma cell line (AA/C1/SB10). Furthermore, we observed that EGF induced the in vitro invasion of the carcinoma cells (AA/C1/SB10) but not the adenoma cells (AA/C1) into a reconstituted basement membrane (Matrigel). This dierence is not due to an inability of the adenoma cells to migrate across the ®lters, nor to increased proliferation of the carcinoma cells. The observation that EGF-induced in vitro invasion into Matrigel does not occur in the adenoma cells indicates that they acquire this malignancy-associated property during progression. Thus, the adenoma cells, which can migrate across collagen coated ®lters see the extracellular matrix as a migratory barrier which the carcinoma cells can overcome in the presence of a motility factor such as EGF. This acquisition of invasive potential in vitro correlates with the ability of the carcinoma cells (AA/ C1/SB10) to form tumours in athymic mice while the adenoma cells (AA/C1) are non-tumorigenic (Williams et al., 1990) . We conclude that the increased levels of the EGF receptor during progression may contribute to the dierence between the adenoma and carcinoma cells; however, other biochemical changes which occur during progression may also be important.
Involvement of c-Src
After EGF treatment we observed a rapid and dramatic re-localisation of c-Src in the carcinoma cell line (AA/C1/SB10). The absence of any similar redistribution in the adenoma cells (AA/C1) suggests that the recruitment of c-Src to the cell periphery may be linked to the biological eect of EGF in these cells. However, it is not known whether the modest elevation in c-Src kinase activity we observed in the carcinoma cell line (AA/C1/BS10) is required for its EGF-induced extracellular redistribution. A study in ®broblasts has demonstrated a direct link between EGF receptor expression and activation of c-Src (Osherov and Levitzki, 1994) , where an EGF-induced threefold increase in c-Src kinase activity was seen in fibroblasts transfected with the EGF receptor which have around 300 000 EGF receptors per cell. This dropped to a 1.5-fold increase in kinase activity in late passage which have around 50% of the parental EGF receptor number. This is consistent with our ®ndings where a small (1.7-fold) reproducible stimulation of c-Src kinase activity was seen in response to EGF in the AA/C1/SB10 carcinoma cells which have around Weernink and Rijksen, 1995) and thrombin stimulated platelets (Clark and Brugge, 1993) . In the latter study the authors demonstrated that the increase in activity was concomitant with a dephosphorylation of Tyr 527 and that this increase in activity preceded the translocation of c-Src to the cytoskeletal fraction. Kaplan and co-workers have also demonstrated that the movement of c-Src to focal adhesions is regulated by phosphorylation of Tyr 527 (Kaplan et al., 1994) . Activated Y527F mutants of c-Src, in which the kinase activity was also abolished, still localised to focal adhesions. A model was proposed for the regulation of c-Src (reviewed in Courtneidge, 1994) in which the inactive form of c-Src is folded in such a way that an intramolecular interaction between Tyr 527 and the SH2 domain takes place, with the SH3 domain also forming an intramolecular interaction. The catalytic activity is low and both the SH2 and SH3 domains are unable to interact with other proteins. Dephosphorylation of Tyr 527 breaks the intramolecular interactions leading to a conformation where the kinase domain is exposed and the SH2 and SH3 domains able to participate in intermolecular interactions, such as the association with focal adhesions.
Involvement of FAK
In ®broblasts FAK has been demonstrated to be involved in cell motility with FAK de®cient fibroblasts being impaired in their motility (Ilic et al., 1995) . Transient phosphorylation of FAK has been linked to increased motility in ®broblasts stimulated with hyaluronan (Hall et al., 1994) and to an increase in migration and invasion of squamous cell carcinoma cells treated with hepatocyte growth factor (Matsumoto et al., 1994), which are both potent motogens. Furthermore increased expression of FAK has been found in invasive tumours of both the breast and colon (Owens et al., 1995) . In the in vitro model described here, we demonstrated a substantial elevation of FAK between the AA/C1 adenoma cells and the AA/C1/ SB10 carcinoma cells, suggesting that it is a later event than the increase in the EGF receptor, which is already upregulated in the transition of the parental PC/AA adneoma cells to the AA/C1 clonogenic variant. Furthermore, FAK was rapidly phosphorylated on tyrosine in response to EGF treatment in the AA/C1/ SB10 carcinoma cells, suggesting that one eect of EGF was to increase focal adhesion turnover in these cells through phosphorylation of FAK (Fincham et al., 1995; Ilic et al., 1995; Richardson and Parsons, 1996) , an event which is associated with cell motility. In contrast there was no phosphorylation of FAK in response to EGF in the adenoma AA/C1 cells. We cannot rule out the possibility that FAK phosphorylation did occur in the AA/C1 cells and that it was below the limit of detection due to the lower levels of FAK protein in the AA/C1 cells. However, phosphorylation of FAK, albeit at very low levels, was seen in untreated AA/C1/SB10 carcinoma cells suggesting that a threshold level of FAK phosphorylation is required to allow cell movement.
The EGF-induced tyrosine phosphorylation of FAK in the AA/C1/SB10 carcinoma cells was rapid and preceded the localisation of c-Src to the cell periphery. In ®broblasts autophosphorylated FAK can only form a stable complex with activated forms of c-Src (Cobb et al., 1994) . This occurs via the c-Src SH2 domain and the FAK autophosphorylation site . It is possible that EGF-induced phosphorylation of FAK participates in the targeting of c-Src, which is also rapidly activated by EGF, to focal adhesions. Work in ®broblasts has demonstrated that c-Src is involved in the regulation of focal adhesions (Kaplan et al., 1994) . This may be via its ability to maintain the phosphorylation status of FAK perhaps by protecting the autophosphorylation site from dephosphorylation by tyrosine phosphatases (Cobb et al., 1994) or by the phosphorylation of other tyrosine residues in FAK which are required for maximal kinase activity (Calalb et al., 1995) .
In summary, we have demonstrated that the EGF receptor is substantially upregulated during the progression of a human adenoma cell line to a carcinoma line in vitro. This, possibly together with deregulation of molecules with which it functionally cooperates, results in EGF-induced invasion of the carcinoma cells into Matrigel. In response to EGF treatment, c-Src was recruited to the cell periphery and FAK, which was also upregulated during the progression, was phosphorylated on tyrosine in the carcinoma cells. Thus EGF induces in vitro invasion of colon carcinoma cells, but not of the adenoma cells from which they were derived, an eect which is linked to altered regulation of both c-Src and FAK.
Materials and methods
Cell culture
Cells were grown in the presence of Swiss 3T3 conditioned DMEM medium (Williams et al., 1990) containing 20% foetal bovine serum (FBS) (batch selected), hydrocortisone sodium succinate (1 mg/ml), insulin (0.2 units/ml), glutamine (2 mM), penicillin (100 units/ml) and streptomycin (100 mg/ml). Routine passage was carried out using 0.1% trypsin/0.1% EDTA. The cells have previously been described in detail (Williams et al., 1990) . Brie¯y, a cell line was derived from a large colonic tubular adenoma with mild dysplasia (PC/AA) from which a non-tumorigenic clonogenic variant was established (AA/C1). Following sequential treatment with sodium butyrate and the carcinogen N-methyl-N'-nitro-N-nitrosoguanidine an anchorage-independent line was isolated, which with time in culture became tumorigenic when injected into nude mice (AA/C1/SB10).
Preparation of cell lysates and immunoprecipitates
Cells were grown to 70% con¯uency in 25 cm 2¯a sks. The monolayer was washed twice with ice-cold phosphate buered saline (PBS) and 0.5 ml lysis buer (10 mM Tris, pH 7.4, 150 mM NaCl, 1% Triton X-100, 0.5% Nonidet P-40, 1 mM EDTA, 10 mM sodium pyrophosphate, 100 mM sodium orthovanadate, 1 mM phenylmethylsulphonyl fluoride, 2 mg/ml aprotinin, 0.5 mM NaF) added. The cells were scraped into Eppendorf tubes, sonicated, then centrifuged for 30 min at 15 000 g at 48C. The resulting supernatant was used for immunoblotting and immunoprecipitates. For immunoprecipitates, cell lysates were precleared with normal rabbit serum and non-speci®c complexes collected with S. aureus by centrifugation. c-Src was immunoprecipitated using MAb327 (Oncogene Science, Cambridge BioScience, Cambridge, UK). 0.2 mg of antibody was added per 100 mg precleared cell lysate and incubated for 2 h at 48C. Immune complexes were collected by addition of S. aureus coated with rabbit anti-mouse IgG and washed three times with lysis buer and used for c-Src immune complex kinase assays. Tyrosine phosphorylated proteins were immunoprecipitated with 2 mg PY20 (Transduction Laboratories, Aniti Research Products, UK) from 1.3 mg of whole cell lysates prepared using the lysis buer described above supplemented with 1 mM DTT and 10 mM b-glycerophosphate. The immune complexes were collected with protein A sepharose coated with rabbit antimouse IgG, washed three times with lysis buer, twice with Tris pH 7.4 containing 2.5% LiCl and resuspended in 26 Laemmli sample buer.
Immune complex c-Src kinase assay c-Src kinase activity was measured in c-Src immune complexes as follows. The immunoprecipitates were washed once in kinase buer (100 mM PIPES, pH 6.8, 20 mM MnCl 2 , 10 mM sodium orthovanadate) and resuspended in 10 ml kinase buer. The c-Src immune complexes were then incubated with [g 32 P]ATP (10 mM, 5 mCi: Amersham, UK sp.ac. 3000 Ci/mmol) and 10 mg acid denatured enolase for 10 min at 208C. The reactions were terminated by addition of 26Laemmli sample buer and the samples boiled for 5 min. Proteins were then resolved by 10% SDS ± PAGE and analysed by autoradiography and densitometry.
Immunoblotting
Samples were separated on 10% SDS-polyacrylamide gels for identi®cation of c-Src or 7% gels for identi®cation of the EGF receptor and FAK. Proteins were then transferred to nitrocellulose by semidry electroblotting. The membranes were incubated with either 1 : 1000 anti-Src MAb327 (Oncogene Science, Cambridge BioScience, Cambridge, UK), 1 : 1000 anti-EGF receptor (UBI, TCS, Buckingham, UK) or 1 : 500 anti-FAK (Transduction Laboratories, Aniti Research Products, UK). The membranes were washed 365 min with PBS/0.2% Tween 20 (PBST) and incubated with the appropriate peroxidase-conjugated secondary antibodies (Amersham, UK) for 30 min. Following incubation with the secondary antibody the membranes were washed for 30 min with PBST and the proteins visualized using enhanced chemiluminescence (Amersham, UK) and quanti®ed by densitometry.
Cell growth
Cells were seeded at 1610 4 per well in 96 well plates and allowed to grow in the presence of 20% FBS for 48 h. The medium was replaced with DMEM containing 1% charcoal stripped serum (CSS) and a range of EGF concentrations. The number of cells was estimated after 5 days using the colorimetric 3-(4,5-dimethylthiazol-2yl)-2,5-diphenyltetrazolium bromide (MTT) dye assay (Plumb et al., 1989) . CGP52411 (a kind gift from Dr N Lydon, Ciba Geigy Pharmaceuticals (Buchdunger et al., 1994) ) was dissolved in DMSO and added at a concentration of 5 mM where indicated. The ®nal concentration of DMSO in the wells was 0.1% (v/v) and had no observed eect on cell growth.
Immuno¯uorescence microscopy
Cells were grown on coverslips for 40 h, ®xed with 3.7% formaldehyde in PBS for 10 min, permeabilized for 30 min with 0.5% Triton X-100/1% BSA in PBS and blocked with 10% FBS in PBS for 30 min. The cells were then incubated with either anti-Src (N2-17, a kind gift from Dr Tony Hunter), anti-vinculin (Sigma Chemical Co.) or anti-FAK (UBI, TCS, Buckingham, UK) antibodies and washed 365 min with 0.025% Tween 80 in PBS and incubated with the appropriate FITC or TRITC-conjugated secondary antibody (Sigma Chemical Co.). The coverslips were washed 365 min with 0.025% Tween 80 in PBS and mounted with Vectashield (Vector Laboratories, Peterborough, UK) and viewed using a BioRad MRC 600 confocal illumination unit linked to a Nikon Diaphot inverted microscope. EGF treated cells were serum-starved for 16 h before addition of EGF (100 ng/ml) for 1 h.
In vitro migration and invasion assays
Movement or invasion of cells into Matrigel (Collaborative Research) was determined as previously described (Hennigan et al., 1994) . Growth factor depleted Matrigel was layered on top of Costar 8 m polycarbonate ®lter transwell units. After the Matrigel had solidi®ed the unit was inverted and 1610 5 cells were positioned on the bottom of the ®lter and allowed to adhere for 2 h. The ®lter unit was then transferred back into the transwell containing 1 ml of DMEM supplemented with 0.5% FBS. DMEM supplemented with EGF (100 ng/ml) was added above the Matrigel and the transwells incubated at 378C for 5 days. The Matrigel and cells were then ®xed with methanol for 10 min, stained with 0.5 mg/ml propidium iodide in PBS for 10 min, washed 365 min in PBS and viewed using a BioRad MRC 600 confocal illumination unit linked to a Nikon Diaphot inverted microscope with a 206objective. Optical sections were scanned at 10 m intervals above the ®lter up to 50 m. The number of cells per optical section is proportional to the number of positive pixels per optical section and was quantitated as described previously (Hennigan et al., 1994) . The data are presented as the number of positive pixels 20 m and above as a percentage of the total number of positive pixels above the ®lter. This represents cells which have moved into the Matrigel and are no longer in contact with the ®lter.
The ability of cells to migrate across a collagen coated 8 m polycarbonate ®lter was also determined. Collagen type IV (Sigma Chemical Co) (50 mg/ml) was added below the ®lter unit in contact with the bottom of the ®lter. Cells were added above the ®lter and allowed to adhere for 2 h. Serum-free medium +EGF (100 ng/ml) was then added above the ®lter. After 18 h the ®lters were washed with PBS, ®xed in methanol for 10 min and stained with 3% Giemsa. The number of cells migrating to the bottom of the ®lter was determined by dissolving the Giemsa stained cells on the bottom of the ®lter in 10% acetic acid and measuring the absorbance at 635 nm.
Scatchard analysis
Cells were plated at 1610 5 in 24 well plates and grown overnight. Following removal of the medium the cells were washed twice with 1 ml binding buer (PBS containing 0.1% (w/v) bovine serum albumin, pH 7.4) and then incubated with human [
125 I]EGF (sp.act. 1430 Ci/mmol; Amersham, UK; concentration range 5.5 ± 0.05 nM) for 1 h at 208C. The unbound EGF was removed by washing the monolayer three times in binding buer. The cells were then lysed in 1 M NaOH containing 0.1% sodium dodecyl sulphate. The solubilised cells were transferred into Eppendorf tubes and the radioactivity measured in a Packard Cobra II Auto-Gamma counter. Nonspeci®c binding was determined using a 100-fold excess of unlabelled ligand. The data were analysed according to the method of Scatchard (1949) .
